{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.90","upperLimit":"15.50","value":"11.60"},{"comment":"The median was not reached, since more than half of the participants in the study had not experienced the event of death at the time of analysis.","groupId":"OG001","lowerLimit":"27.30","upperLimit":"NA","value":"NA"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG002","lowerLimit":"1.10","upperLimit":"NA","value":"1.20"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG003","lowerLimit":"13.60","upperLimit":"NA","value":"25.20"},{"groupId":"OG004","lowerLimit":"5.00","upperLimit":"27.50","value":"11.60"},{"groupId":"OG005","lowerLimit":"4.40","upperLimit":"17.90","value":"10.20"},{"groupId":"OG006","lowerLimit":"1.00","upperLimit":"19.10","value":"14.00"},{"comment":"Since the upper confidence limits for the survivor function lies above 0.5, it is not possible to estimate the upper confidence limit for the median.","groupId":"OG007","lowerLimit":"1.60","upperLimit":"NA","value":"18.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"OS is defined as the time in months from the first dose of study drug until death from any cause. For the participants who are not known to have died by the end of study follow-up, OS will be censored on the date the participants was last known to be alive. OS is calculated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 1; FT-2102 (Single Agent)"},{"description":"Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 2; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG002","title":"Phase 2: Cohort 3; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG003","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG004","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"OG005","title":"Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG006","title":"Phase 2: Cohort 7; FT-2102 (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG007","title":"Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"MEDIAN","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102.","reportingStatus":"POSTED","timeFrame":"Phase 2: From first dose of study drug until death from any cause (up to 82 months)","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}